peptides
Peptide Therapy for Longevity: What the Research Actually Shows (and What You're Paying For)
July 4, 2026
You're 47, your bloodwork looks fine on paper, and your doctor has nothing to offer except "keep doing what you're doing." Meanwhile, you're reading about peptide protocols that claim to slow biological ageing, restore growth hormone signalling, and cut recovery time in half. The clinics running those protocols range from serious medical operations to spray-and-pray telehealth mills. The science behind the peptides themselves is more substantiated than the marketing around them — and the gap between what the research actually says and what the clinics charge is worth understanding before you hand over your credit card.
What the Growth Hormone Secretagogues Actually Do
The longevity use case for most peptide protocols centres on growth hormone secretagogues — peptides that stimulate the pituitary to release GH rather than replacing it directly. Sermorelin, a 29-amino-acid analogue of GHRH, received FDA approval in 1997 for paediatric GH deficiency before being widely adopted for adult off-label use. CJC-1295 arrived later as a research compound. It carries a DAC (Drug Affinity Complex) modification that extends its half-life from minutes to roughly 8 days, which is why most protocols combine it with ipamorelin rather than running it alone.
The data on these compounds in healthy adults is genuinely limited. A 2006 study by Teichman et al. found that CJC-1295 produced a 2- to 10-fold increase in mean GH levels and a 1.5- to 3-fold increase in IGF-1 levels across 36 healthy adults aged 21–61 — but that trial lasted only 63 days and wasn't designed to measure longevity endpoints. What clinics extrapolate from those numbers — reduced visceral fat, improved lean mass, better sleep architecture — is plausible based on the known downstream effects of restored GH pulsatility, but none of it has been tested with the rigour of a pharmaceutical trial.
The BPC-157 Case: Repair and Recovery
BPC-157 occupies a different corner of the longevity conversation. A 15-amino-acid peptide derived from a gastric protein, it's used primarily for connective tissue repair, gut health, and neuroprotection. The animal data is substantial — dozens of rodent studies showing accelerated tendon-to-bone healing, reduced inflammation, and gastric mucosal protection — but as of mid-2026, no Phase II or Phase III human trial has been published. The FDA has not approved BPC-157 for any indication, and in 2024 the agency moved to classify it as a Category 2 bulk drug substance, which significantly restricted compound pharmacies from including it in preparations.
Clinics operating outside the US — particularly in the UK and Europe — have more latitude here. If you're based in Britain and want access to a supervised BPC-157 protocol, the BPC-157 clinics in the UK directory is a more practical starting point than navigating US telehealth restrictions.
What the Protocols Actually Cost
Pricing in 2026 varies enough to suggest the market hasn't settled on what these interventions are worth. A typical 3-month CJC-1295/ipamorelin protocol through a US telehealth platform runs $250–$450 for the peptides alone, with some programs bundling labs and physician oversight into a monthly membership starting around $199/month. Sermorelin runs cheaper — often $150–$220 per vial for a month's supply at standard dosing of 200–300 mcg per injection, five days a week.
The outliers are concierge and functional medicine clinics that bundle peptides into broader longevity packages. Those programs routinely reach $3,000–$8,000 per year when you include hormone panels, continuous glucose monitoring, and quarterly telehealth reviews. The relevant question is what you're getting beyond the peptides themselves — ask explicitly before you sign anything.
For comparison shopping across platforms, the online peptide programs directory covers most of the major US-accessible options in one place. Yucca Health and System Labs are two of the more established telehealth platforms, with structured protocols that include initial labs and physician sign-off rather than just a prescription pad.
The IGF-1 Monitoring Question
One concrete way to evaluate whether a longevity peptide protocol is being run responsibly is whether the provider tracks IGF-1. Growth hormone secretagogues work by raising GH pulsatility, which drives liver production of IGF-1 — and IGF-1 is the biomarker that confirms something is happening. The standard reference range runs roughly 100–300 ng/mL for adults aged 40–60, with many longevity physicians aiming to move patients from the low end of that range toward 200–250 ng/mL without exceeding the upper bound.
Providers who don't test IGF-1 at baseline and again at 6–8 weeks are flying blind. IGF-1 sustained above 300 ng/mL over months carries theoretical cancer promotion risk — particularly relevant for anyone with a family history of hormone-sensitive cancers. The Endocrine Society's 2019 clinical practice guideline on adult growth hormone deficiency explicitly recommends monitoring IGF-1 throughout GH-stimulating treatment, and that recommendation applies whether you're clinically deficient or pursuing optimisation.
What's Actually Hype
Two things in the longevity peptide market don't hold up under scrutiny.
First, oral peptide delivery. Multiple clinics now sell oral BPC-157 capsules despite the fact that peptides are degraded by gastric acid. The bioavailability argument for oral administration rests on a 2022 study using a proprietary arginate salt form, and that data has not been independently replicated at scale. If you're paying for oral peptides at injectable prices, you're likely absorbing very little of the active compound.
Second, stack complexity. Some concierge protocols layer five or six peptides simultaneously — PT-141, thymosin alpha-1, MOTS-c, epithalon, and others — at price points above $800 per month. The evidence on each of these individually is preliminary; the evidence on combining them is essentially nonexistent. That doesn't mean the combinations don't work. It means no published trial has tested whether the stack does anything the individual peptides don't.
The Practical Takeaway
Three things matter more than anything else when evaluating a longevity peptide program: whether baseline and follow-up IGF-1 testing is included, whether the physician is actually reviewing those numbers rather than auto-signing labs, and whether the compounds are sourced from an accredited 503B compounding pharmacy. Those aren't premium features — they're the floor. Programs that can't confirm all three aren't offering medicine; they're offering the feeling of medicine.
Browse the peptide clinics directory to filter by protocol type, geography, and what's included in the base price before you commit to anything.
Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.